ClinicalTrials.gg
RecruitingNCT06445062Updated Sep 22, 2026

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

A Phase 1/2 interventional study of RMC-6236 and mFOLFOX6 regimen in Colorectal Cancer, CRC and Pancreatic Ductal Adenocarcinoma, sponsored by Revolution Medicines, Inc.. Recruiting at 32 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by Revolution Medicines, Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started May 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
1,130
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 187 studies testing cetuximab in Colorectal Neoplasms — 35 open to participants now, 43 under way, 7 of them phase 3. Cetuximab · Colorectal Neoplasms.

Planned enrollment
7th of 185
1,130 · median 60
Started
2024
with 16 others
Phase 1/2
20 of 187
6 open now
Primary completion
2028-09
later than 29 of 42 live
Registered
170th of 187
by date

Among the 187 studies testing cetuximab in Colorectal Neoplasms, this one is the 7th largest by planned enrollment of the 185 interventional ones that give a count, is one of 17 that started in 2024, is one of 20 in phase 1/2, reaches primary completion later than 29 of the 42 other live ones, and was the 170th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

35 of the 187 studies testing cetuximab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

29 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing cetuximab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents.

The current subprotocols include the following:

Subprotocol A: RMC-6236 + 5-fluorouracil-based regimens

Subprotocol B: RMC-6236 + cetuximab with or without mFOLFOX6

Subprotocol C: RMC-6236 + gemcitabine + nab-paclitaxel

Subprotocol D: RMC-9805 with or without RMC-6236 + 5-fluorouracil-based regimens

Subprotocol E: RMC-9805 with or without RMC-6236 + cetuximab with or without mFOLFOX6

Subprotocol F: RMC-9805 with or without RMC-6236 + gemcitabine + nab-paclitaxel

Subprotocol G: RMC-9805 + cetuximab + FOLFIRI

Read the detailed description

The platform study design allows combinations of RAS(ON) inhibitors with other anticancer agents to be evaluated in patients with RAS-mutated solid tumors with a focus on GI cancers.

This is an open-label platform study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard of Care (SOC) or with novel agents, and to define the Recommended Phase 2 Dose and Schedule (RP2DS). Enrollment of patients with RAS mutations will be specified in each subprotocol.

Subprotocol A is an open-label, multicenter study of RMC-6236 in combination with 5-fluorouracil-based regimens in patients with treatment-naïve unresectable or metastatic colorectal cancer or treatment-naïve metastatic pancreatic ductal adenocarcinoma. Subprotocol B is an open-label, multicenter study of RMC-6236 in combination with cetuximab with or without mFOLFOX6 in patients with unresectable or metastatic colorectal cancer or patients with previously treated or treatment-naïve metastatic pancreatic ductal adenocarcinoma. Subprotocol C is an open-label, multicenter study of RMC-6236 in combination with gemcitabine and nab-paclitaxel in patients with treatment-naïve metastatic pancreatic ductal adenocarcinoma. Subprotocol D is an open-label, multicenter study of RMC-9805 with or without RMC-6236 in combination with 5-fluorouracil-based regimens in patients with RAS G12D-mutant unresectable or metastatic colorectal cancer or metastatic pancreatic ductal adenocarcinoma. Subprotocol E is an open-label, multicenter study of RMC-9805 with or without RMC-6236 in combination with cetuximab-based therapies with or without mFOLFOX6 in patients with RAS G12D-mutant unresectable or metastatic colorectal cancer or metastatic pancreatic ductal adenocarcinoma. Subprotocol F is an open-label, multicenter study of RMC-9805 with or without RMC-6236 in combination with gemcitabine and nab-paclitaxel in patients with RAS G12D-mutant metastatic pancreatic ductal adenocarcinoma. Subprotocol G is an open-label, multicenter study of RMC-9805 with cetuximab and FOLFIRI in patients with previously treated, RAS G12D-mutated metastatic colorectal cancer.

03

Conditions studied

  • Colorectal Cancer
  • CRC
  • Pancreatic Ductal Adenocarcinoma
  • PDAC
  • Gastrointestinal Cancer
  • Metastatic Pancreatic Ductal Adenocarcinoma

Keywords

  • CRC
  • PDAC
  • RAS Mutation
  • KRAS G12X
  • Colorectal Cancer
  • Pancreatic Cancer
  • Pancreatic Ductal Carcinoma
  • KRAS Q61 Mutation
  • KRAS G12 Mutation
  • RAS Wild-type
  • RAS G12D Mutation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All Patients (unless otherwise noted):

  • ≥ 18 years of age
  • PS is 0 to 1
  • Adequate organ function as outlined by the study
  • or cytologically documented pancreatic carcinoma or poorly differentiated pancreatic carcinoma with disease or RAS-mutated, histologically or cytologically confirmed colorectal adenocarcinoma with documented unresectable or metastatic disease (Subprotocol A, B, C and G)
  • Presence of RAS G12D mutation (Subprotocol D, E, F, G)

Exclusion criteria

Exclusion Criteria:

All Patients:

  • Primary central nervous system (CNS) tumors
  • Impaired gastrointestinal (GI) function that may significantly alter the absorption of RMC drugs
  • Major surgery within 28 days of first dose

Other inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,130 participants (estimated)

Study arms

  • Experimental
    Subprotocol A: RAS-mutated unresectable or metastatic CRC or metastatic PDAC

    RMC-6236 (QD) and bevacizumab with 5-fluorouracil-based regimens

    Drug: RMC-6236 · Drug: mFOLFOX6 regimen · Drug: bevacizumab · Drug: mFOLFIRINOX regimen

  • Experimental
    Subprotocol B: RAS-mutated unresectable or metastatic CRC or metastatic PDAC

    RMC-6236 (QD) and cetuximab with or without mFOLFOX6

    Drug: RMC-6236 · Drug: mFOLFOX6 regimen · Drug: cetuximab

  • Experimental
    Subprotocol C: metastatic PDAC

    RMC-6236 (QD) and gemcitabine with nab-paclitaxel

    Drug: RMC-6236 · Drug: gemcitabine · Drug: nab-paclitaxel

  • Experimental
    Subprotocol D: RAS G12D-mutated unresectable or metastatic CRC or metastatic PDAC

    RMC-9805 (QD or BID) with or without RMC-6236 (QD), and bevacizumab with 5-fluorouracil- based regimens

    Drug: RMC-6236 · Drug: mFOLFOX6 regimen · Drug: bevacizumab · Drug: mFOLFIRINOX regimen · Drug: RMC-9805

  • Experimental
    Subprotocol E: RAS G12D-mutated unresectable or metastatic CRC or metastatic PDAC

    RMC-9805 (QD or BID) with or without RMC-6236 (QD), and cetuximab with or without mFOLFOX6

    Drug: RMC-6236 · Drug: mFOLFOX6 regimen · Drug: cetuximab · Drug: RMC-9805

  • Experimental
    Subprotocol F: RAS G12D-mutated metastatic PDAC

    RMC-9805 (QD or BID) with or without RMC-6236 (QD), and gemcitabine with nab-paclitaxel

    Drug: RMC-6236 · Drug: gemcitabine · Drug: nab-paclitaxel · Drug: RMC-9805

  • Experimental
    Subprotocol G: RAS G12D-mutated metastatic CRC

    RMC-9805 (QD) and cetuximab with FOLFIRI

    Drug: cetuximab · Drug: RMC-9805 · Drug: FOLFIRI regimen

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse events (Subprotocols A-F)

    Evaluate the safety and tolerability in the study population characterized by incidence, abnormal laboratory assessments, severity, and seriousness of adverse events in relation to the study treatment.

    Time frame: Up to 3 years

  2. Dose limiting toxicities (Subprotocols A-F)

    Number of participants with dose limiting toxicities

    Time frame: 28 days

  3. Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as assessed by Blinded Independent Central Review (BICR)(Subprotocol G)

    Time frame: Up to 3 years

Secondary outcomes

  1. Pharmacokinetics of RMC-6236 (Subprotocols A-F)

    Blood concentration of RMC-6236 over time

    Time frame: 21 weeks

  2. Pharmacokinetics of RMC-9805 (Subprotocols D-G)

    Blood concentration of RMC-9805 over time

    Time frame: 21 weeks

  3. ORR assessed by Investigator (Subprotocols A-G)

    Overall Response Rate per RECIST v1.1

    Time frame: Up to 3 years

  4. DOR (Subprotocols A-G)

    Duration of Response per RECIST v1.1

    Time frame: Up to 3 years

  5. DCR (Subprotocols A-G)

    Incidence of Response per RECIST v1.1

    Time frame: Up to 3 years

  6. TTR (Subprotocols A-G)

    Time to Response per RECIST v1.1

    Time frame: Up to 3 years

  7. PFS (Subprotocols A-G)

    Progression Free Survival per RECIST v1.1

    Time frame: Up to 3 years

  8. PFS Rate at 6 and 12 Months (Subprotocol G)

    Time frame: Up to 3 years

  9. OS (Subprotocols A-F)

    Overall Survival

    Time frame: Up to 3 years

  10. Overall Survival Rate at 12 Months (Subprotocol G)

    Time frame: Up to 3 years

  11. Number of Participants with Adverse Events (Subprotocol G)

    Time frame: Up to 3 years

07

Study locations

32 of 32 sites recruiting
08

References and documents

Publications

  • Cregg J, Edwards AV, Chang S, Lee BJ, Knox JE, Tomlinson ACA, Marquez A, Liu Y, Freilich R, Aay N, Wang Y, Jiang L, Jiang J, Wang Z, Flagella M, Wildes D, Smith JAM, Singh M, Wang Z, Gill AL, Koltun ES. Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers. J Med Chem. 2025 Mar 27;68(6):6064-6083. doi: 10.1021/acs.jmedchem.4c02314. Epub 2025 Mar 8. PubMed 40056080 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Sep 2028, 52 months after the start.

Of 158 industry-sponsored phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 82. This study's planned 52 months is below that.

Counting every sponsor, half of 260 studies reached it within 59 months; a quarter within 36 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2024
First posted
Jun 6, 2024
StartActual
May 24, 2024
Primary completionEst.
Sep 30, 2028
CompletionEst.
Mar 30, 2030
Last update
Sep 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06445062
Responsible party
Sponsor
First posted
Jun 6, 2024
Start date
May 24, 2024
Primary completion
Sep 30, 2028 (estimated)
Completion
Mar 30, 2030 (estimated)
Last update
Sep 22, 2026

Study contacts

Revolution Medicines
Contact
medinfo@revmed.com
1-844-2-REVMED
Study Director
study director · Revolution Medicines

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Daraxonrasib · Cetuximab · Zoldonrasib

Start the discussion